Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.

Objectives Mini-Sentinel is a pilot project sponsored by the U.S. Food and Drug Administration to create an active surveillance system to monitor the safety of FDA-regulated medical products. We assessed the capability of the Mini-Sentinel pilot to provide prevalence rates of medication use among pr...

Descripción completa

Detalles Bibliográficos
Publicado en:Maternal & Child Health Journal Vol. 20; no. 4; pp. 895 - 904
Autores principales: Andrade, Susan, Toh, Sengwee, Houstoun, Monika, Mott, Katrina, Pitts, Marilyn, Kieswetter, Caren, Ceresa, Carrie, Haffenreffer, Katherine, Reichman, Marsha
Formato: research tables/charts Journal Article
Publicado: Springer Nature Apr2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113778723&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 113778723
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10927875
        N9J
      jtl: Maternal & Child Health Journal
      issn: 10927875
      maglogo: N
    pubinfo:
      dt: Apr2016
      vid: 20
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        113778723
        113778723
        113778723
        10.1007/s10995-015-1878-8
        113778723
      ppf: 895
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.
      aug:
        au:
          Andrade, Susan
          Toh, Sengwee
          Houstoun, Monika
          Mott, Katrina
          Pitts, Marilyn
          Kieswetter, Caren
          Ceresa, Carrie
          Haffenreffer, Katherine
          Reichman, Marsha
        affil: Meyers Primary Care Institute (Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School), 630 Plantation St. Worcester 01605 USA
      sug:
        subj:
          Drug Monitoring In Pregnancy
          Drug Therapy In Pregnancy
          Human
          Pregnancy
          Female
          Algorithms
          Child
          Adolescence
          Adult
          Middle Age
          Descriptive Statistics
          Childbirth
          Multiple Sclerosis
          Lupus Erythematosus, Systemic
          Data Analysis Software
          Childbirth, Premature
          Pregnancy, Prolonged
          Databases
          Funding Source
          Child: 6-12 years
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Female
      ab: Objectives Mini-Sentinel is a pilot project sponsored by the U.S. Food and Drug Administration to create an active surveillance system to monitor the safety of FDA-regulated medical products. We assessed the capability of the Mini-Sentinel pilot to provide prevalence rates of medication use among pregnant women delivering a liveborn infant. Methods An algorithm was developed to identify pregnancies for a reusable analytic tool to be executed against the Mini-Sentinel Distributed Database. Diagnosis and procedure codes were used to identify women ages 10-54 years delivering a liveborn infant between April 2001 and December 2012. A comparison group of age- and date-matched nonpregnant women was identified. The analytic code was distributed to all 18 Mini-Sentinel data partners. The use of specific medications, selected because of concerns about their safe use during pregnancy, was identified from outpatient dispensing data. We determined the frequency of pregnancy episodes and nonpregnant episodes exposed to medications of interest, any time during the pregnant/matched nonpregnant period, and during each trimester. Results The analytic tool successfully identified 1,678,410 live birth deliveries meeting the eligibility criteria. The prevalence of use at any time during pregnancy was 0.38 % for angiotensin-converting enzyme inhibitors and 0.22 % for statins. For ≤0.05 % of pregnancy episodes, the woman was dispensed warfarin, methotrexate, ribavirin, or mycophenolate. Conclusions The analytic tool developed for this study can be used to assess the use of medications during pregnancy as safety issues arise, and is adaptable to include different medications, observation periods, pre-existing conditions, and enrollment criteria.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N